A new study published in BMC Health Services Research highlights the potential of biosimilar trastuzumab to revolutionize treatment for early-stage HER2-positive breast cancer in Thailand. Researchers Lochid-amnuay and Kongsakon conducted a comprehensive cost-utility and budget impact analysis, demonstrating that biosimilars could expand access to life-saving therapies while easing financial burdens on the healthcare system.
Breast cancer remains the most common cancer among women worldwide, with HER2-positive cases—accounting for approximately 20% of all breast cancers—known for their aggressive progression and poorer prognosis. Trastuzumab, the pioneering monoclonal antibody therapy targeting HER2, has significantly improved survival rates. However, its high cost has limited accessibility, particularly in low- and middle-income countries like Thailand.
Biosimilars, highly similar versions of existing biologics with no meaningful differences in safety or efficacy, offer a promising solution. “The introduction of biosimilars can generate substantial healthcare savings while maintaining treatment quality,” the study notes, underscoring the opportunity for Thailand to adopt these therapies more broadly.
Using a robust cost-utility modeling framework, the researchers compared biosimilar trastuzumab with its branded counterpart. They assessed direct and indirect treatment costs alongside quality-adjusted life years (QALYs) gained. The analysis concluded that switching to biosimilars not only conserves resources but also delivers high-quality care, positively impacting patient outcomes.
The study’s budget impact assessment further revealed that adopting biosimilars could significantly reduce national healthcare expenditures for breast cancer treatment. These savings could be redirected to other critical healthcare services, promoting a more equitable distribution of medical resources across the population.
Experts emphasize that the findings provide critical guidance for policymakers planning the future of cancer care in Thailand. Expanding biosimilar use presents an opportunity to improve patient access while addressing pressing economic challenges. By integrating biosimilars into treatment protocols, the country could achieve tangible reductions in breast cancer morbidity and mortality.
The research also highlights the broader importance of ongoing evaluation and stakeholder collaboration. Healthcare providers, payers, and patients must engage in continuous dialogue to ensure that biosimilars are safely and effectively incorporated into clinical practice. Delays in adopting cost-effective alternatives could result in missed opportunities to invest in preventive care and other essential health services.
Public education and awareness are also crucial. Misconceptions about biosimilars can hinder acceptance among both patients and healthcare professionals. Targeted initiatives to highlight the safety, efficacy, and rigorous testing of these treatments are essential for successful implementation.
Regulatory support is another key factor. Policymakers and regulatory agencies must create frameworks that facilitate the approval and development of biosimilars while maintaining rigorous safety and efficacy standards. Collaboration among the government, pharmaceutical companies, and healthcare providers can foster trust and accelerate integration into standard care.
In conclusion, the study by Lochid-amnuay and Kongsakon underscores that the adoption of biosimilar trastuzumab is not merely an economic choice—it is a critical step toward equitable, effective cancer care. By leveraging the cost advantages of biosimilars, Thailand can expand patient access, optimize healthcare spending, and align its treatment strategies with global trends in sustainable, high-quality cancer therapy.
